Purchase Order 75N91024P00118
Award Date 12/15/23
Potential Completion Date 1/31/24
Potential Value $16K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $17,354.17 firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Invivoscribe, Inc. for the provision of biological reagents. The contract has an ultimate completion date of September 28, 2024. Invivoscribe, a for-profit manufacturer of precision diagnostics, will provide biological reagents, kits, assays, and other molecular diagnostics products to support the NCI's cancer research...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $17,210 firm fixed price purchase order to Invivoscribe, Inc. for biological kits. The place of performance is in San Diego, California. No set-aside designation was used for this contract. Invivoscribe will deliver the requested biological kits to the National Cancer Institute by April 22, 2024 to support the Institute's cancer research efforts. As the sole awardee, Invivoscribe will be...
- <p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for $15,955.00 on March 18, 2020, for drugs and biologicals with an ultimate completion date of April 30, 2020. The order carries no small business set-aside. Work is performed in San Diego, California. The contract is firm fixed price, reflecting a commercial purchase of specialized biological kits and reagents to support cancer research initiatives.</p>
- <p>The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $12,038.04 firm fixed price purchase order to Invivoscribe, Inc. for assays. The place of performance is in San Diego, California and the completion date is January 31, 2024. As no set aside was used, the award was unrestricted. Invivoscribe will deliver the requested assays to support the National Cancer Institute's research efforts.</p>
- This firm fixed price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Invivoscribe, Inc., a for-profit manufacturer of precision diagnostics specializing in reagents, kits, and services for clinical molecular diagnostics and translational research. The $19,295.17 contract is for the provision of BIOLOGICAL KITS to support the NCI's cancer research initiatives, including advancing the understanding of tumor...
- This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Invivoscribe, Inc., a for-profit manufacturer of biological research products based in San Diego, California. The $18,250.00 contract is for the delivery of a "BIOLOGICAL KIT" to support cancer research initiatives. The contract does not have a set-aside designation, indicating that Invivoscribe was selected based on its specialized...
- This is a $18,370.00 firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health, to Invivoscribe, Inc., a for-profit manufacturer of biological products. The contract is for the delivery of "BIOLOGICAL KITS" and does not have a set-aside designation, indicating Invivoscribe competed for the award based on its specialized expertise. The contract has an ultimate completion date of April 26, 2025...
- The National Cancer Institute (NCI), a component of the Department of Health and Human Services, awarded a firm fixed-price purchase order valued at $57,435 to Invivoscribe, Inc. on March 5, 2026, for the procurement of InvivoScribe IGH+IGK B-cell clonality assays. This non-competitive sole-source award was issued under the statutory authority of 10 USC 2304(c)(1) and was not subject to any set-aside designation. The assays and associated specimen size control ladder reagents will support the...
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $120,611.20 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract is for reagents and consumables to be provided between September 10, 2023 and October 9, 2023 at the prime contractor's listed place of performance in San Diego. No additional details were provided on the original solicitation or associated...
- <p>The National Cancer Institute awarded a purchase order to Invivoscribe, Inc. for biological kits with a ceiling value of $12,370.00, effective December 18, 2020 and completing January 16, 2021. The order is firm fixed price with no set-aside. Performance occurs in San Diego, California.</p>